Andrew Mann

Associate, Washington, DC



Drew Mann is a member of the Firm's Global Antitrust/Competition practice group. Drew’s practice focuses on advising clients on a range of international competition issues, with a particular focus on government investigations, multijurisdictional merger clearances and litigation. He regularly advises clients on a range of international antitrust topics, including joint ventures and competitor collaborations, gun-jumping and information exchanges, price fixing and market allocations, exclusive dealing, joint purchasing and joint selling arrangements

Prior to joining the Firm, Drew was an attorney at the US Federal Trade Commission (FTC) in the Bureau of Competition's Anticompetitive Practices Division. While at the FTC, Drew led or was actively involved in numerous investigations and litigations involving proposed or consummated mergers, price fixing, monopolization, predatory pricing, tying and state action claims.

Drew was also previously a Special Assistant United States Attorney in the Alexandria, Virginia, US Attorney's Office, in the Eastern District of Virginia (the Rocket Docket) where he focused on criminal prosecution.

Bars and Courts
Virginia State Bar
District of Columbia Bar
University of Richmond

T.C. Williams School of Law

University of Richmond

Robins School of Business

Brigham Young University


Some of Drew's recent multijurisdictional merger clearance work includes representing:

  • Panasonic Corporation in its 20% strategic equity investment in Blue Yonder, a leading US end-to-end supply chain software provider with an estimated enterprise value of US$5.5 billion.
  • Baxter International Inc. in its acquisition of the Seprafilm adhesion barrier device and related assets from Sanofi S.A.
  • Saudi Aramco, the world's largest oil company by production, in its US$69.1 billion acquisition of a 70% stake in Saudi Basic Industries Corporation (SABIC), one of the world's largest petrochemicals companies.
  • Zimmer Holdings Inc., a global leader and manufacturer of orthopedic implants, in its US$13.35 billion acquisition of Biomet Inc.

Annual Review of Antitrust Law Developments, 2013 and 2012, (contributing author)